The earnings call presented notable scientific and regulatory advancements, particularly with BA3182 and Oz-V, and strategic partnerships aimed at non-dilutive funding. However, financial constraints, including decreased cash reserves and ongoing net losses, underline significant operational challenges.

Company Guidance -

Q3 2025

During the BioAtla Second Quarter 2025 Earnings Call, several key metrics and projections were highlighted, reflecting the company's progress and strategic direction. BioAtla is advancing its clinical trials, particularly focusing on the dual conditionally binding EpCAM CD3 T cell engager, BA3182, showing promise in Phase I trials with stable disease achieved in all five evaluable patients in the latest cohort. The company anticipates a Phase I data readout in the second half of 2025 and further dose expansion in the first half of 2026. Additionally, the CAB-ROR2-ADC Oz-V has demonstrated a 45% objective response rate (ORR) in metastatic HPV-positive head and neck cancer, significantly outperforming the 3.4% ORR of standard therapies. Financially, R&D expenses decreased to $13.7 million from $16.2 million year-over-year, with a net loss of $18.7 million compared to $21.1 million in 2024, and the company reported cash and equivalents of $18.2 million as of June 30, 2025. BioAtla aims to manage expenses and secure non-dilutive funding through partnerships, while also preparing for an FDA meeting to discuss a pivotal Phase III trial for Oz-V.

Progress in BA3182 Phase I Study

BioAtla's dual conditionally binding EpCAM CD3 T cell engager, BA3182, showed evidence of objective tumor reductions in 7 heavily pretreated adenocarcinoma patients across multiple solid tumors. All 5 evaluable patients in the most recent cohort achieved stable disease and continue on treatment.

Strong Performance of CAB-ROR2-ADC Oz-V

Oz-V demonstrated a 45% objective response rate (ORR) and 11.6 months median overall survival in patients with metastatic HPV-positive head and neck cancer, significantly outperforming the standard of care.

Positive FDA Guidance for Oz-V

BioAtla received actionable FDA guidance on a pivotal trial in head and neck cancer, with potential for accelerated approval based on compelling ORR and OS data.

Clinical Progress of Mec-V and Evalstotug

Mec-V showed exceptional overall survival in mKRAS non-small cell lung cancer patients, with 1-year and 2-year survival rates of 67% and 59%. Evalstotug demonstrated potent antitumor activity with reduced immune-mediated adverse events in metastatic melanoma.

Strategic Partnerships and Funding

BioAtla is making progress in partnering discussions, with diligence completed for one asset and reaching the term sheet stage, aiming to close the transaction by year-end.

BioAtla (BCAB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BCAB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.30 / -	-0.22	―	―	―
Aug 07, 2025	2025 (Q2)	-0.28 / -0.32	-0.44	27.27% (+0.12)
May 06, 2025	2025 (Q1)	-0.29 / -0.26	-0.48	45.83% (+0.22)	―
Mar 27, 2025	2024 (Q4)	-0.39 / -0.30	-0.56	46.43% (+0.26)	―
Nov 07, 2024	2024 (Q3)	-0.41 / -0.22	-0.7	68.57% (+0.48)	―
Aug 08, 2024	2024 (Q2)	-0.45 / -0.44	-0.75	41.33% (+0.31)	―
May 14, 2024	2024 (Q1)	-0.54 / -0.48	-0.58	17.24% (+0.10)	―
Mar 26, 2024	2023 (Q4)	-0.79 / -0.56	-0.634	11.67% (+0.07)	―
Nov 07, 2023	2023 (Q3)	-0.77 / -0.70	-0.69	-1.45% (-0.01)	―
Aug 01, 2023	2023 (Q2)	-0.64 / -0.75	-0.77	2.60% (+0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BCAB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$0.38	$0.35	-7.89%
May 06, 2025	$0.48	$0.45	-6.25%
Mar 27, 2025	$0.39	$0.37	-5.13%
Nov 07, 2024	$2.22	$2.10	-5.41%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.